The Most Favored Nation (MFN) drug pricing policy ties U.S. medicine prices to those in countries with strict government price controls. This may sound like a win for patients, but MFN imports the very systems that limit access, delay innovation, and lead to higher death rates abroad—especially from diseases like cancer. In Europe, where these policies have long been in place, patients often wait months or years to access new treatments, and many breakthrough therapies never arrive at all. If implemented in the U.S., MFN could mean fewer medicines, slower innovation, and hundreds of thousands of preventable deaths—every year.
America has the best access to new cancer treatments in the world. If we dismantle that, U.S. patients will be the first to feel it. But make no mistake—patients worldwide will suffer.
Because in the end, MFN doesn’t mean “Most Favored Nation.” It means: Medicines for No-one.
More MFN Resources:
Executive Order Announcing MFN Drug Pricing Policy
ASBM Statement Opposing MFN Drug Pricing
Global Colon Cancer Association Statement Opposing MFN Executive Order
Andrew Spiegel Op-Ed: “How President Trump’s Executive Order Will Put An End To Pharmaceutical Breakthroughs”
‘Most-Favored Nation’ Drug Pricing Has Three Significant Problems – April 14, 2025 – USC Schaeffer
How Trump’s New Drug Pricing EO Differs From Past Attempts – John Barkett & Julia Bonavitacola
Unpacking President Trump’s New Executive Order on “Most-Favored-Nation” Prescription Drug Pricing
